Tikcro Technologies Ltd. powered by a novel 3D antigen design technology, generates new ‎antibodies that block receptor/ligand surface domains of immune modulators and re-‎activate the body’s immune system to fight cancer. Our antibodies are at various pre-‎clinical stages.

Tikcro Technologies Reports Third Quarter 2017 Results

In-progress of Pre Clinical Trials of Full-Human CTLA-4 Antibodies

TIKRF (Ordinary Share)

Last price;
Change (%)
Data as of 2018-05-25
Minimum 20 minute delay
Refresh quote
© Copyright 2015, Tikcro Ltd. | Legal - Terms of use | All rights reserved | Site by Imaginet